CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 11 enrolled
Drug / intervention
silicon phthalocyanine 4 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01800838
NCT01800838Phase 1Completed
CompareCT.gov

Silicon Phthalocyanine Pc4 for Photodynamic Therapy of Cutaneous T-cell Lymphoma: Single and Repeated Photoexposures

Kevin Cooper MD·interventional·Posted Feb 28, 2013·Updated May 16, 2019

In Brief

A Phase 1 clinical trial evaluating silicon phthalocyanine 4, photodynamic therapy, and 2 other interventions for Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma and 6 related conditions. Completed, enrolled 11 participants across 1 site.

Detailed Summary

This phase I trial studies the side effects and best dose of silicon phthalocyanine 4 and photodynamic therapy in treating patients with stage IA-IIA cutaneous T-cell non-Hodgkin lymphoma. Photodynamic therapy (PDT) uses a drug, silicon phthalocyanine 4, that becomes active when it is exposed to a certain kind of light. When the drug is active, cancer cells are killed. This may be effective against cutaneous T-cell non-Hodgkin lymphoma. Funding Source - FDA OOPD

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IA Mycosis Fungoides/Sezary Syndrome, Stage IB Mycosis Fungoides/Sezary Syndrome, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIA Mycosis Fungoides/Sezary Syndrome
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 28, 2013
Enrollment StartApr 1, 2013
Primary CompletionSep 1, 2014
Study CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 13.3 years ago

Interventions

silicon phthalocyanine 4drug

Given topically

photodynamic therapydrug

Undergo PDT

pharmacological studyother

Correlative studies

laboratory biomarker analysisother

Correlative studies